Relay Therapeutics: Q1 Earnings Insights

Relay Therapeutics (NASDAQ:RLAY) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:05 PM. Here’s what…

Relay Therapeutics (NASDAQ:RLAY) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:05 PM.

Here’s what investors need to know about the announcement.

Earnings

Relay Therapeutics missed estimated earnings by 13.04%, reporting an EPS of $-0.78 versus an estimate of $-0.69.

Revenue was down $193 thousand from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.14 which was followed by a 2.12% drop in the share price the next day.

Here’s a look at Relay Therapeutics’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -0.70 -0.71 -0.63 -0.62
EPS Actual -0.56 -0.76 -0.71 -0.57
Revenue Estimate 3.30M 1.66M 1.93M 170K
Revenue Actual 253K 344K 365K 419K

Listen to the earnings announcement yourself by clicking here.

To track all earnings releases for Relay Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses

Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday its financial results for the full year and three months ended Dec. 31, 2023. Net revenue grew to CA$33 million ($24.3 million), from CA$22.1 million in 2022, representing roughly a 50% year-over-year increase. "Over the years we have invested in our infrastructure as a high quality and high-capacity pharmaceutical grade manufacturer, allowing us to grow sales with new opportunities and markets, without additional investment into capital or resources," David Pidduck said. "We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

MEDIF